Boston Therapeutics Completes Enrollment of Patients With

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Boston Therapeutics Completes Enrollment of Patients With Type 2 Diabetes in Phase IIb Study on BTI-320 in the U.S.

MANCHESTER, NH--(Marketwired - Aug 20, 2014) - Boston Therapeutics, Inc. ( OTCQB : BTHE ), a developer of complex carbohydrate therapeutics to treat diabetes, has completed enrollment of its Phase IIb clinical study on BTI-320 in the United States. The study, SD-002, is being conducted by Accumed Research Associates in Garden City, NY.

The U.S. trial enrolled patients with Type 2 diabetes who are currently being treated with metformin. The patients were administered BTI-320 using a randomized, double-blind, placebo-controlled, dose-ranging, three-way cross-over study design. Patients' blood glucose were monitored and their postprandial (after-meal) blood glucose levels were measured following a test meal. The primary endpoint of the study is the evaluation of the effect of BTI-320 compared to placebo in the area under the curve (AUC) of glucose and secondarily, on insulin levels in the blood for four hours following intake of the meal.

David Platt, Ph.D., Chief Executive Officer of Boston Therapeutics, said, "We are pleased to have completed enrollment in this trial and look forward to reporting its results. As with its companion trial in France, this U.S. trial is designed to build upon the positive results from our Dartmouth Medical Center Phase IIa trial for BTI-320, published last year in the peer-reviewed journal Endocrine Practice . In that Phase IIa study, BTI-320 was well tolerated in patients taking various anti-diabetic agents, including metformin. These Phase IIb trials, which focus on patients taking only metformin, are the next step in the investigation of this compound as a potential adjunct to metformin in patients living with Type 2 diabetes. We believe it is important to better control glucose levels throughout the day, given the many complications that stem from uncontrolled diabetes."

About BTI-320

BTI-320 is a non-systemic, new generation alpha glucosidase inhibitor-based tablet developed to reduce post-meal elevation of blood glucose. BTI-320 is a proprietary polysaccharide to be taken before meals and works in the gastrointestinal tract, non-systemically, to block the action of carbohydrate-hydrolyzing enzymes that break down complex carbohydrates into simple sugars, reducing the availability of glucose for absorption into the bloodstream.

About Boston Therapeutics, Inc. Boston Therapeutics, headquartered in Manchester, NH, ( OTCQB : BTHE ) is an innovator in designing compounds using complex carbohydrate chemistry. The company's product pipeline is focused on developing and commercializing therapeutic molecules that address diabetes, including: BTI-320, a non-systemic therapeutic tablet developed to reduce post-meal glucose elevation, and IPOXYN, an injectable anti-necrosis drug designed initially to treat lower limb ischemia associated with diabetes. The company also produces and sells SUGARDOWN ® , a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose. More information is available at www.bostonti.com .

Cautionary Note Regarding Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding the clinical trials are subject to factors beyond our control and provide no assurance of FDA approval of any of our future drug development plans. Our clinical trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would affect our estimates regarding timing, and we may not be able to achieve the desired results. Any significant delays or unanticipated costs in any subsequent drug trial could delay obtaining meaningful results from Phase II studies and/or preparing for Phase III studies with the current cash on hand.

Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse effect on our ability to achieve revenues from our approved products. Plans regarding development, approval and marketing of any of our compounds, including BTI-320, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. We have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional risk and other factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2013, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements, and actual results may differ materially from the results anticipated in our forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

© Boston Therapeutics, Inc. All rights reserved.

Contact: Boston Therapeutics, Inc. Anthony Squeglia Chief Financial Officer Phone: 603-935-9799 Email: anthony.squeglia@bostonti.com www.bostonti.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PARRIS Partners Earn 2026 Plaintiff Lawyer Recognition

Updated Category News Views 95

A $58.4 million jury number can make a courtroom sound like a slot machine, until the final settlement lands at $21 million. That gap is the part people ought to stare at before getting carried away by another plaintiff-lawyer honor roll. The Daily Journal has named PARRIS Law Firm partners Alexander R. Wheeler and Khail A. Parris to its 2026 Top Plaintiff Lawyers special...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 49

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading
Mining's Biodiversity Map Sharpens Location Risks

Updated Category News Views 208

Twelve thousand pins on a map do not settle the mining industry's nature problem, but they do make it much harder to pretend the problem is evenly spread. ICMM's new Global Mining and Metals Biodiversity Dataset overlays 12,000 large-scale formal mining, smelting, refining and processing facilities with ecosystem-condition and conservation indicators. For investors...

Continue Reading
SAGA's Radar Assays Tighten the Trapper North Case

Updated Category News Views 188

Rock that keeps showing up where the model says it should is the sort of boring news a junior miner desperately needs. SAGA Metals has put out fresh assay results from Radar’s Trapper North area, and the useful part is not merely a loud grade in one hole. It is the apparent persistence of thick titanium-vanadium-iron oxide mineralization across tighter-spaced drilling....

Continue Reading
Oracle Takes AI to Construction's Messy Project Middle

Updated Category News Views 164

A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...

Continue Reading
Norfolk Southern's 200-Year Campaign Meets a Hard Market

Updated Category News Views 83

Two centuries of railroad history can stir the blood, but it does not move a single carload by itself. Norfolk Southern has opened its 200-year railroading celebration with the GeneratioNS campaign, a three-locomotive NS 200 commemorative series, and plans for public events across its network. For a railroad with deep roots and very modern operational pressures, this is...

Continue Reading
Whole-House Remodels Need a Plan Before Any Finishes

Updated Category News Views 47

A remodel gets expensive the minute somebody falls in love with tile before checking what sits behind the wall. Adam Sherman’s central point in the HelloNation article is refreshingly unglamorous: treat the house as one working system before treating it as a collection of rooms crying out for cosmetic rescue. That sounds obvious until you see how often a kitchen...

Continue Reading
Zoomlion’s Australian Service Push Looks Built to Last

Updated Category News Views 41

Five Australian business centres are one thing; getting a stalled crane or earthmover moving again is the whole ballgame. Zoomlion’s Nov. 4 customer gathering in Sydney matters because Chairman and CEO Zhan Chunxin kept the discussion on the unglamorous stuff: product quality, technical support, parts availability and local training. That is exactly where an equipment...

Continue Reading
Early Dog Guarding Signs Matter Before a Sudden Growl

Updated Category News Views 104

A bowl, a chewed-up toy, or a patch of couch can turn tense in a heartbeat. That is why the useful part of Brian Manning's guidance is not some fantasy of making every dog endlessly tolerant; it is learning to notice discomfort while there is still room to back off safely. For anybody watching the pet-care and behavior-training field, this is the kind of plainspoken...

Continue Reading
Katahdin's Portland Branch Bet Moves Downtown in 2027

Updated Category News Views 141

Exchange Street is getting a real-world vote of confidence, and that is more interesting than another app update ever will be. Katahdin Trust intends to open a full-service branch at 120 Exchange Street in downtown Portland, with renovations slated to begin early in 2027 and an opening expected later that year. For a Maine community bank with nearly $1.2 billion in...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover the Monport MEGA: Revolutionizing Laser Engraving

Updated Category News Views 100

Monport Launches the MEGA: A Game Changer in Laser Engraving Monport Laser is excited to unveil the MEGA, the revolutionary desktop CO2 laser engraving machine that is set to redefine the standards of efficiency and safety in the industry. This innovative machine embodies a blend of advanced technology and user-friendly design, ensuring that both professionals and...

Continue Reading
Key Insights on Recent Managerial Transactions at Digitalist

Updated Category News Views 107

Recent Managerial Transactions at Digitalist Group Digitalist Group Oy has seen significant managerial activities recently, particularly involving key board members. The transactions not only reflect the movements within the company but also provide insights into the internal management strategies being implemented. Understanding the Notification Requirement The...

Continue Reading
Gold Prices Hold Steady Amid Economic Signals and Tariff Talks

Updated Category News Views 147

Gold Prices Resilient Despite Mixed Economic Factors Gold prices have shown little movement in recent Asian trading sessions. Investors are closely watching potential trade tariffs proposed by the incoming U.S. administration, while a recent dip in the dollar is providing some support for the precious metal. Throughout December, bullion prices experienced some losses due...

Continue Reading
Transforming Bitcoin Mining: HAKA MINING's Innovative Solutions

Updated Category News Views 275

Harnessing the Future of Bitcoin Mining HAKA MINING is making waves in the cryptocurrency sector with its dedicated approach to cloud mining. This UK-based company is not only providing opportunities for passive income but is also championing sustainability in energy use. This innovative cloud mining service empowers users to accumulate cryptocurrency efficiently and...

Continue Reading
RWE Unveils Solar Project, Boosting Jobs and Local Economy

Updated Category News Views 248

RWE Hits Milestone with New Solar Farm Development RWE is celebrating a significant advancement as onsite construction begins for the 98 MWac Union Ridge Solar farm, demonstrating a robust commitment to renewable energy and job creation. This project is positioned to generate jobs and foster economic opportunities in the surrounding regions. Collaborative Efforts with...

Continue Reading